Elise Wang is a Partner on the Public Structured Finance group at Deerfield and joined the Firm in 2010. Ms. Wang provides extensive research and analysis on individual companies operating in the healthcare industry in both the US and Europe. Ms. Wang is a board member of Jaguar Gene Therapy. Prior to Deerfield, Ms. Wang was a Senior Research Analyst and Managing Director covering the biotechnology sector at PaineWebber and Citigroup. She began her career in healthcare as a venture capitalist and banker at PaineWebber and was an officer of PaineWebber Development Corporation, which managed nearly $1 billion in assets representing three PaineWebber funds and several research and development limited partnerships (RDLPs) invested in biotechnology and high technology companies. Ms. Wang holds an A.B. in Engineering Sciences with a specialty in Biomechanics from Harvard University and an M.B.A. from Harvard Business School.